A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice
V. Dasari, K. Beckett, S. Horsefield, G. Ambalathingal, R. Khanna
This paper develops a bivalent CMV vaccine using gB and polyepitope protein with CpG1018, showing durable humoral and cellular immunity in HLA-expressing mice.
bioRxiv · Mar 2, 2022Immunology